These results would reveal that only one single immunodominant helper peptide can elicit both specific Th1-dominant CD4+ T cell responses and Ab responses, suggesting that helper peptide would be a potent cancer vaccine without combination with killer and/or helper peptides [45, 46]. The gene discussed is CD4; the disease is cancer.